NEW YORK, Feb. 12, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on SAGE, SRPT, SRRA, and SRNE which can be accessed for free by signing up to www.wallstequities.com/registration. On Friday, February 09, 2018, the NASDAQ Composite ended the
Cambridge, Massachusetts headquartered Sage Therapeutics Inc.'s stock finished Friday's session 8.37% lower at $152.15 with a total trading volume of 3.43 million shares, which was above its three months average volume of 978.86 thousand shares. The Company's shares have advanced 142.82% in the previous three months and 220.05% over the past twelve months. The stock is trading above its 200-day moving average by 58.38%. Additionally, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have a Relative Strength Index (RSI) of 32.30. Get the full research report on SAGE for free by clicking below at: www.wallstequities.com/registration/?symbol=SAGE
On Friday, shares in Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc. recorded a trading volume of 4.59 million shares, which was above its three months average volume of 1.63 million shares. The stock ended the session 3.55% lower at $55.14. The Company's shares have advanced 87.93% over the last twelve months. The stock is trading above its 200-day moving average by 21.44%. Moreover, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, have an RSI of 35.88.
On January 22nd, 2018, research firm RBC Capital Markets initiated an 'Outperform' rating on the Company's stock. Get access to our top-rated research, including the free report on SRPT at: www.wallstequities.com/registration/?symbol=SRPT
Vancouver, Canada headquartered Sierra Oncology Inc.'s shares closed the day 4.20% lower at $2.74. The stock recorded a trading volume of 577,753 shares. The Company's shares have gained 41.97% over the previous three months and 102.96% over the last twelve months. The stock is trading above its 200-day moving average by 41.00%. Additionally, shares of Sierra Oncology, which engages in developing DNA Damage Response therapeutics for the treatment of patients with cancer, have an RSI of 38.12. Click here to subscribe for a free membership which welcomes you with our report on SRRA at: www.wallstequities.com/registration/?symbol=SRRA
Shares in San Diego, California-based Sorrento Therapeutics Inc. finished 3.55% lower at $6.80. The stock recorded a trading volume of 2.72 million shares, which was above its three months average volume of 2.01 million shares. The Company's shares have advanced 45.45% in the last month, 161.54% in the previous three months, and 23.64% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 43.37% and 153.81%, respectively. Furthermore, shares of Sorrento Therapeutics, which engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide, have an RSI of 56.53.
On January 16th, 2018, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $20 a share to $30 a share. Join our big investor community at Wall St. Equities today and get your free report on SRNE at: www.wallstequities.com/registration/?symbol=SRNE
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-biotechs-investors----sage-therapeutics-sarepta-therapeutics-sierra-oncology-and-sorrento-therapeutics-300596924.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!